The ESMO Gynaecological Cancers Congress 2023

Description

The ESMO Gynaecological Cancers Congress 2023

has become an essential annual appointment for oncology professionals treating patients with such malignancies – the place to learn the latest promising news, acquire high quality education and exchange ideas.

 Topics:

1. ADCs in gynaecological cancers Introduction.mp4
2. ADCs in gynaecological cancers Q&A.mp4
3. ADCs in gynaecological cancers Role of ADCs in cervical cancer treatment in the era of immunotherapy.mp4
4. ADCs in gynaecological cancers Role of ADCs in cervical cancer treatment in the era of immunotherapy.pdf
5. ADCs in gynaecological cancers The evolving ADC treatment landscape in ovarian cancer.mp4
6. ADCs in gynaecological cancers The evolving ADC treatment landscape in ovarian cancer.pdf
7. ADCs in gynaecological cancers The new challenge ADC class effects, on off-target adverse reactions and their interdisciplinary management.mp4
8. ADCs in gynaecological cancers The new challenge ADC class effects, on off-target adverse reactions and their interdisciplinary management.pdf
9. ADCs in gynaecological cancers Understanding the basics Structure, key properties, mechanism of action, optimal diagnostic test to determine the
10. target.mp4
11. ADCs in gynaecological cancers Understanding the basics Structure, key properties, mechanism of action, optimal diagnostic test to determine the
12. target.pdf
13. AstraZeneca – Long-term survival Evidence from first-line PARPi maintenance trials.mp4
14. AstraZeneca – Long-term survival Integrating the latest data into clinical practice.mp4
15. AstraZeneca – Long-term survival Welcome and introduction.mp4
16. Endometrial cancer Beyond immunotherapy What is the role of HER2, p53 and other molecular targets in the recurrent.mp4
17. Endometrial cancer Beyond immunotherapy What is the role of HER2, p53 and other molecular targets in the recurrent.pdf
18. Endometrial cancer Introduction.mp4
19. Endometrial cancer Introduction.pdf
20. Endometrial cancer Is immunotherapy changing the face of recurrent metastatic endometrial cancer.mp4
21. Endometrial cancer Is immunotherapy changing the face of recurrent metastatic endometrial cancer.pdf
22. Endometrial cancer Q&A.mp4
23. Endometrial cancer Revisiting the adjuvant therapy in endometrial cancer ESMO Guidelines.mp4
24. Endometrial cancer Revisiting the adjuvant therapy in endometrial cancer ESMO Guidelines.pdf
25. ESMO Colloquium supported Concluding remarks.mp4
26. ESMO Colloquium supported Emerging molecular profiling models for advanced endometrial cancer.mp4
27. ESMO Colloquium supported Introduction.mp4
28. ESMO Colloquium supported Q&A.mp4
29. ESMO Colloquium supported Research insights- New immunotherapy combinations in clinical development for gynecological malignancies.mp4
30. ESMO Colloquium supported The landscape of approved immune checkpoint inhibitors and TKI combinations in advanced endometrial cancer.mp4
31. final_programme_gynae23hybrid.pdf
32. GSK – Shifting the treatment paradigm of OC EC Live Q&A and discussion.mp4
33. GSK – Shifting the treatment paradigm of OC EC Where are we going with EC- Aiming to improve outcomes in primary advanced or recurrent.mp4
34. GSK – Shifting the treatment paradigm of OC EC Where are we going with OC- Evolving the management of 1L.mp4
35. GSK – Shifting the treatment paradigm of OC EC Where are we now- Latest advances in treatment of gynecologic cancer.mp4
36. How hot is HIPEC treatment in ovarian cancer HIPEC is not IT (CON).pdf
37. How hot is HIPEC treatment in ovarian cancer Introduction and first vote.mp4
38. How hot is HIPEC treatment in ovarian cancer Introduction and first vote.pdf
39. How hot is HIPEC treatment in ovarian cancer Second vote and conclusions.mp4
40. How hot is HIPEC treatment in ovarian cancer Second vote and conclusions.pdf
41. How hot is HIPEC treatment in ovarian cancer The data absolutely support integration of HIPEC into primary ovarian cancer management (PRO).mp4
42. How hot is HIPEC treatment in ovarian cancer The data absolutely support integration of HIPEC into primary ovarian cancer management (PRO).pdf
43. How to interpret overall survival data with PARP inhibitors Is there a biological rationale to support decremental impact on overall survival.mp4
44. How to interpret overall survival data with PARP inhibitors Is there a biological rationale to support decremental impact on overall survival.pdf
45. How to interpret overall survival data with PARP inhibitors Is there clinical evidence to support the link between PARPi use and a negative impact on OS.mp4
46. How to interpret overall survival data with PARP inhibitors Is there clinical evidence to support the link between PARPi use and a negative impact on OS.pdf
47. How to interpret overall survival data with PARP inhibitors Q&A.mp4
48. How to interpret overall survival data with PARP inhibitors Why are we having this Symposium Recent regulatory actions by FDA.mp4
49. How to interpret overall survival data with PARP inhibitors Why are we having this Symposium Recent regulatory actions by FDA.pdf
50. Is cervical cancer still an orphan disease Immunotherapy in cervical cancer A paradigm shift.mp4
51. Is cervical cancer still an orphan disease Immunotherapy in cervical cancer A paradigm shift.pdf
52. Is cervical cancer still an orphan disease Innovative techniques in radiation oncology to increase cure and reduce toxicity.mp4
53. Is cervical cancer still an orphan disease Innovative techniques in radiation oncology to increase cure and reduce toxicity.pdf
54. Is cervical cancer still an orphan disease Molecular profiling and pathology of cervical cancer patients.mp4
55. Is cervical cancer still an orphan disease Molecular profiling and pathology of cervical cancer patients.pdf
56. Is cervical cancer still an orphan disease Q&A.mp4
57. Keynote address Introduction to the Keynote lecture.mp4
58. Keynote address Pandemomics Challenging assumptions in gynecologic oncology.mp4
59. Keynote address Pandemomics Challenging assumptions in gynecologic oncology.pdf
60. Mini Oral session 1MO – Identification of RAD51 foci in cancer-associated circulating cells and their association.mp4
61. Mini Oral session 1MO – Identification of RAD51 foci in cancer-associated circulating cells and their association.pdf
62. Mini Oral session 22MO – Homologous Recombination Gene Mutations in Uterine Serous Cancer.mp4
63. Mini Oral session 22MO – Homologous Recombination Gene Mutations in Uterine Serous Cancer.pdf
64. Mini Oral session 36MO – Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC).mp4
65. Mini Oral session 36MO – Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC).pdf
66. Mini Oral session 37MO – Niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer.mp4
67. Mini Oral session 37MO – Niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer.pdf
68. Mini Oral session 39MO – Clinical evaluation of a low-coverage whole-genome test for homologous recombination deficiency detection in ovarian cancer.mp4
69. Mini Oral session 39MO – Clinical evaluation of a low-coverage whole-genome test for homologous recombination deficiency detection in ovarian cancer.pdf
70. Mini Oral session 40MO – Targetable Gene Mutations in Mucinous Ovarian Cancer.mp4
71. Mini Oral session 40MO – Targetable Gene Mutations in Mucinous Ovarian Cancer.pdf
72. Mini Oral session 74MO – Clinical outcomes for pelvic node-positive vulvar carcinoma in the PET and IMRT era.mp4
73. Mini Oral session 74MO – Clinical outcomes for pelvic node-positive vulvar carcinoma in the PET and IMRT era.pdf
74. Mini Oral session Invited Discussant of abstracts 22MO, 38MO, 39MO and 1MO.mp4
75. Mini Oral session Invited Discussant of abstracts 22MO, 38MO, 39MO and 1MO.pdf
76. Mini Oral session Invited Discussant of abstracts 36MO and 37MO.mp4
77. Mini Oral session Invited Discussant of abstracts 36MO and 37MO.pdf
78. Mini Oral session Invited Discussant of abstracts 40MO and 74MO.mp4
79. Mini Oral session Invited Discussant of abstracts 40MO and 74MO.pdf
80. Poster Display session 10P – Neoadjuvant chemotherapy with bevacizumab for IIb stage cervical cancer.pdf
81. Poster Display session 11P – Conization before radical hysterectomy in early cervical cancer A Korean multi-center study.pdf
82. Poster Display session 12P – Tisotumab vedotin in recurrent or metastatic cervical cancer.pdf
83. Poster Display session 13P – Cervical cancer screening in a Basic Health Unit in South of Brazil impact of the COVID-19 pandemic.pdf
84. Poster Display session 14P – Clinical Outcomes Of Women Who Attend The Cameroon Baptist Convention Health Services.pdf
85. Poster Display session 15P – Efficacy and safety analysis of recombinant human endostatin (Endostar).pdf
86. Poster Display session 16P – Impact of Preoperative versus Postoperative radiotherapy and radical hysterectomy without systemic.pdf
87. Poster Display session 17P – Impact of adjuvant chemoradiotherapy on survival outcome compared to other treatment modalities for cervical cancer stage IIIc.pdf
88. Poster Display session 18P – Prospective Randomized Comparison of Quality of Life in Locally Advanced Cervical Cancer treated with Intracavitary or Interstitial Brachytherapy.pdf
89. Poster Display session 19P – Neoadjuvant chemotherapy followed by radical surgery vs chemoradiotherapy in patients with cervical cancer (stage IIB, FIGO 2018).pdf
90. Poster Display session 20P – Randomized Comparison of four Radiotherapy schedules in locally advanced cervical cancer A Prospective study.pdf
91. Poster Display session 21TiP – Molecular Alterations Predictive of Outcome in Early Staged Cervical Cancer.pdf
92. Poster Display session 23P – Pre-treatment inflammatory indexes predict the clinical outcome of patients with endometrial cancer a MITO24 study.pdf
93. Poster Display session 24P – A phase II trial of Docetaxel cisplatin chemotherapy followed by pelvic radiation therapy.pdf
94. Poster Display session 25P – Prognostic classification of endometrial cancer according to transcriptomic-based immunophenotype.pdf
95. Poster Display session 26P – Demographics and survival outcomes in patients (pts) with advanced or recurrent (A R) endometrial cancer (EC) in the English real-world (RW) setting.pdf
96. Poster Display session 27P – Treatment Outcomes and Toxicity Profiles in South Asian patients of High-Risk Endometrial Cancer treated with PORTEC-3 trial regimen.pdf
97. Poster Display session 28P – Clinicopathologic characteristics and oncologic outcomes of mismatch repair-deficient microsatellite instability-high endometrial cancer.pdf
98. Poster Display session 29P – Outcomes of patients with intermediate-high risk early stage endometrial cancer after surgery according to adjuvant treatment.pdf
99. Poster Display session 2P – Outcomes of patients with gynecological tumors harboring HER2 defects.pdf
100. Poster Display session 30P – Validation of MODEPLEX technology for the determination of POLE hotspot mutations in endometrial carcinoma samples.pdf
101. Poster Display session 31P – Uterine Cancer Metastasis Patterns and Racial Disparities A SEER Database Population Study 2010-2019.pdf
102. Poster Display session 3P – NaPi2b Expression in High Grade Serous Ovarian Cancer results from combined data sets.pdf
103. Poster Display session 41P – Phase 1 analysis of ubamatamab (MUC16xCD3 bispecific antibody) in patients with recurrent ovarian cancer.pdf
104. Poster Display session 42P – Efficacy of maintenance with PARPi in advanced ovarian cancer according to the location of BRCA mutation.pdf
105. Poster Display session 43P – Time to next treatment (TTNT) of first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC).pdf
106. Poster Display session 44P – Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in patients with recurrent ovarian cancer.pdf
107. Poster Display session 45P – MITO39 Effiacy and tolerability of PLD-Trabectedin in the treatment of relapsed Ovarian Cancer after maintenance therapy with PARP-i.pdf
108. Poster Display session 46P – Long-term residual chemotherapy-induced peripheral neuropathy (CIPN) and relationship with single nucleotides polymorphisms (SNPs).pdf
109. Poster Display session 47P – Platinum rechallenge (PtRc) for high-grade epithelial ovarian cancer (HGEOC) patients (pts) considered not eligible for further platinum therapy.pdf
110. Poster Display session 48P – Response to chemotherapy following PARP inhibition in ovarian cancer (OC) patients at Mount Vernon Cancer Centre.pdf
111. Poster Display session 49P – First Report on Pan-Immune-Inflammation Value as a New Prognostic Factor in Ovarian Cancer A Biomarker Analysis of OVANORDEST-1 Study.pdf
112. Poster Display session 4P – Evaluation of Antitumor Activity and Immunogenic Cell Death (ICD) Induction.pdf
113. Poster Display session 50P – Can We Learn From Failures A Systematic Review and Metanalysis of Phase III Trials in Platinum Resistant Ovarian Cancer.pdf
114. Poster Display session 51P – Efficacy of PARP inhibitors in patients with advanced high grade serous ovarian cancer according to BRCA domain mutations.pdf
115. Poster Display session 52P – Real world data of Niraparib in platinum sensitive relapsed ovarian cancer a multicenter experience of the MITO group.pdf
116. Poster Display session 53P – Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients.pdf
117. Poster Display session 54P – Fallopian tube cancer and ovarian cancer A real-world comparison of epidemiological patterns, clinical outcomes, and mutational landscape.pdf
118. Poster Display session 55P – Evolution of Genetic Testing after Ovarian Cancer (OC) diagnosis.pdf
119. Poster Display session 56P – Differential response to DNA damaging agents of patients carrying the germline BRCA1 c.211 A-G pathogenic variant.pdf
120. Poster Display session 57P – International Ovarian Tumor Analysis (IOTA) Simple Ultrasound Rules and Risk of Malignancy Index in differentiating benign.pdf
121. Poster Display session 58P – The lymphocyte activation gene-3 (LAG-3) protein expression in tumor-infiltrating lymphocytes is associated with a poor prognosis.pdf
122. Poster Display session 59P – Expression of CD47 a potent `don’t eat me’ signal’ in ovarian cancer (OC)- Correlation with other immune features and evolution under neoadjuvant.pdf
123. Poster Display session 5P – Physiologically relevant treatment models to investigate epigenetic mechanisms driving platinum.pdf
124. Poster Display session 60P – Deciphering CD8+ T-cell-related gene signatures in the tumor microenvironment to predict the immunotherapy response and prognosis.pdf
125. Poster Display session 61P – Fluorescent detection of epithelial cells in intraoperative flushes in ovarian cancer in the liquid biochip format.pdf
126. Poster Display session 62P – Development of deep learning-based auto-segmentation algorithms to diagnose and indicate peritoneal carcinomatosis lesions of ovarian cancer.pdf
127. Poster Display session 63P – Redefining the role of CA 19-9 as a prognostic marker in Epithelial Ovarian Cancer.pdf
128. Poster Display session 64P – Malignant Brenner Tumor of the Ovary- impact of adjuvant chemotherapy, age, race, laterality and stage on survival outcome.pdf
129. Poster Display session 65P – Clinical outcomes in ovarian clear cell carcinoma A UK single centre experience.pdf
130. Poster Display session 66P – PD-L1 expression following neoadjuvant chemotherapy is upregulated and serves as a prognostic factor.pdf
131. Poster Display session 67P – Survival and reproductive outcomes of patients with malignant ovarian germ cell tumors, a retrospective analysis.pdf
132. Poster Display session 68P – Prognosis of ovarian cancer patients with the Mexican founder mutation (a BRCA1 long genomic rearrangement).pdf
133. Poster Display session 69P – Relationship between BRCA genotype by location and duration of response to iPARP treatment. Real-life data.pdf
134. Poster Display session 6P – Unveiling the impact of intra-tumor heterogeneity in treatment response to achieve personalized medicine.pdf
135. Poster Display session 70P – Prognostic factors and outcome in ovarian adult granulosa-cell tumours a retrospective real-world data.pdf
136. Poster Display session 71P – survival outcomes of patients with recurrent malignant ovarian germ cell tumors, a retrospective analysis from a tertiary cancer center.pdf
137. Poster Display session 72TiP – AVALON Trial Phase 2b Study of Maveropepimut-S and Low-Dose Cyclophosphamide in Subjects with Platinum-Resistant.pdf
138. Poster Display session 73TiP – Niraparib maintenance in first line ovarian cancer MITO 40 an observational real-life study.pdf
139. Poster Display session 75P – Clinical characteristics and Desensitization protocol of Chemotherapy-induced Hypersensitivity reactions in patients with gynecologic cancer.pdf
140. Poster Display session 76P – To do or not to do Endometrial biopsy in younger women with abnormal uterine bleeding.pdf
141. Poster Display session 77P – The impact of COVID-19 on gynecological cancer diagnoses in Greece.pdf
142. Poster Display session 78P – Electronic tool for high grade Adverse Event (AE) reporting in gynecology (gyne) clinical trials (ClinT) at Princess Margaret Cancer Centre (PM).pdf
143. Poster Display session 79P – The situation of gynecological cancer before and after COVID – 19 pandemic years in Kosovo.pdf
144. Poster Display session 7P – Integration of whole genome sequencing (WGS) into NHS pathways for high-grade ovarian cancer (HGOC).pdf
145. Poster Display session 80P – Efficacy, FDA approval, innovativeness, clinical evidence, and price of breast, ovarian, endometrial, and cervical cancer drugs.pdf
146. Poster Display session 8P – NXP800 versus cisplatin in ARID1a-mutated Ovarian Clear Cell Carcinoma xenograft models.pdf
147. Poster Display session 9P – The Survival Effect And Prognost-c Factors Of Residual Tumor Conf.pdf
148. Proffered Paper session 32O – 5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts).mp4
149. Proffered Paper session 32O – 5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts).pdf
150. Proffered Paper session 33O – PRIMA ENGOT-OV26 GOG-3012 study long-term conditional PFS.mp4
151. Proffered Paper session 33O – PRIMA ENGOT-OV26 GOG-3012 study long-term conditional PFS.pdf
152. Proffered Paper session 34O – ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss.mp4
153. Proffered Paper session 34O – ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss.pdf
154. Proffered Paper session 35O – Overall Survival of Niraparib with Individualized Starting Dose as Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer.mp4
155. Proffered Paper session 35O – Overall Survival of Niraparib with Individualized Starting Dose as Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer.pdf
156. Proffered Paper session Invited Discussant of abstract 34O.mp4
157. Proffered Paper session Invited Discussant of abstract 34O.pdf
158. Proffered Paper session Invited Discussant of abstract 35O.mp4
159. Proffered Paper session Invited Discussant of abstract 35O.pdf
160. Proffered Paper session Invited Discussant of abstracts 32O and 33O.mp4
161. Proffered Paper session Invited Discussant of abstracts 32O and 33O.pdf
162. Proffered Paper session Q&A and discussion.mp4
163. Rare cancers Introduction.mp4
164. Rare cancers Is immune therapy definitely required for all clear cell carcinoma.mp4
165. Rare cancers Is immune therapy definitely required for all clear cell carcinoma.pdf
166. Rare cancers Q&A.mp4
167. Rare cancers State-of-the-art management in carcinosarcoma From the biology to treatment.mp4
168. Rare cancers State-of-the-art management in carcinosarcoma From the biology to treatment.pdf
169. Rare cancers Which drugs could be relevant for LGSC The present and future.mp4
170. Rare cancers Which drugs could be relevant for LGSC The present and future.pdf
171. Regeneron – VELOCISUITE- Leveraging Regeneron’s technologies to produce an innovative therapeutic pipeline.mp4
172. Seagen – Driving towards the future Key messages and close.mp4
173. Seagen – Driving towards the future Welcome and introduction.mp4
174. Seagen – Driving towards the future What has changed and what’s next in the 1L setting for r_m CC-.mp4
175. Seagen – Driving towards the future What’s new and how can we improve 2L management of r_m CC-.mp4
176. Welcome from the Congress Chairs Do we still need radical surgery in the PARP inhibitor era.mp4
177. Welcome from the Congress Chairs Do we still need radical surgery in the PARP inhibitor era.pdf
178. Welcome from the Congress Chairs How to select the best first line maintenance treatment.mp4
179. Welcome from the Congress Chairs How to select the best first line maintenance treatment.pdf
180. Welcome from the Congress Chairs Introduction.mp4
181. Welcome from the Congress Chairs New treatment in the current ovarian cancer beyond ADCs.mp4
182. Welcome from the Congress Chairs New treatment in the current ovarian cancer beyond ADCs.pdf
183. Welcome from the Congress Chairs PARP inhibitors Mechanism of resistance and how to overcome.mp4
184. Welcome from the Congress Chairs PARP inhibitors Mechanism of resistance and how to overcome.pdf
185. Welcome from the Congress Chairs Q&A.mp4
186. Welcome from the Congress Chairs Welcome to the ESMO Gynaecological Cancers Congress 2023.mp4
187. Welcome from the Congress Chairs Welcome to the ESMO Gynaecological Cancers Congress 2023.pdf